MCID: ATR011
MIFTS: 68

Atrial Fibrillation

Categories: Rare diseases, Genetic diseases, Cardiovascular diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 36 28 28 51 40 3 41 14 69 59 59
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
ICD10 32 I48
ICD9CM 34 427.31
MeSH 41 D001281
NCIt 46 C50466
KEGG 36 H00731
UMLS 69 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 59
About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm.AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly.In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should.People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid.AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as a-fib, is related to familial atrial fibrillation and progressive familial heart block, type ia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Amiodarone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

MedlinePlus : 40 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Electrical activity of a normal heart (left) and a heart with atrial fibrillation (right).

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 familial atrial fibrillation 33.7 ABCC9 GJA5 KCNA5 KCNE2 KCNJ2 KCNQ1
2 progressive familial heart block, type ia 31.2 GJA5 SCN5A
3 atrioventricular block 31.0 HCN4 KCNE2 KCNQ1 NPPB SCN5A
4 congestive heart failure 31.0 ACE ADRB1 NPPA NPPB
5 ventricular fibrillation, paroxysmal familial, 1 30.9 KCNE2 KCNQ1 SCN5A
6 short qt syndrome 30.9 KCNE2 KCNJ2 KCNQ1 SCN3B SCN5A
7 right bundle branch block 30.9 HCN4 SCN1B SCN2B SCN3B SCN5A
8 systolic heart failure 30.9 ACE ADRB1 NPPB
9 catecholaminergic polymorphic ventricular tachycardia 30.8 KCNE2 KCNJ2 KCNQ1 SCN5A
10 cardiac arrhythmia 30.8 KCNE2 KCNQ1 SCN5A
11 acute myocardial infarction 30.7 ACE ADRB1 NPPA NPPB
12 first-degree atrioventricular block 30.7 GJA5 SCN5A
13 coronary artery anomaly 30.7 ACE ADRB1 NPPA NPPB
14 syncope 30.7 KCNJ2 KCNQ1 NPPA NPPB SCN5A
15 aortic valve disease 2 30.7 ACE MYL4 NPPA NPPB
16 brugada syndrome 30.7 ABCC9 HCN4 KCNE2 KCNQ1 SCN1B SCN2B
17 atrial standstill 30.6 GJA5 NPPA SCN5A
18 central sleep apnea 30.6 NPPA NPPB
19 third-degree atrioventricular block 30.5 HCN4 KCNE2 NPPB SCN5A
20 heart disease 30.4 ACE ADRB1 GJA5 KCNE2 KCNJ2 KCNQ1
21 hypertension, essential 30.4 ACE ADRB1 NPPA NPPB
22 left ventricular noncompaction 30.4 HCN4 KCNQ1 SCN5A
23 cardiac arrest 30.3 ACE KCNQ1 SCN5A
24 pulmonary hypertension 30.0 ACE KCNA5 NPPA NPPB
25 long qt syndrome 30.0 ADRB1 HCN4 KCNA5 KCNE2 KCNJ2 KCNQ1
26 dilated cardiomyopathy 30.0 ABCC9 ACE ADRB1 GJA5 KCNQ1 NPPA
27 atrial standstill 1 29.9 ACE ADRB1 GJA5 NPPB SCN1B SCN5A
28 atrial fibrillation, familial, 15 12.5
29 atrial fibrillation, familial, 3 12.5
30 atrial fibrillation, familial, 4 12.5
31 atrial fibrillation, familial, 6 12.5
32 atrial fibrillation, familial, 7 12.5
33 atrial fibrillation, familial, 9 12.5
34 atrial fibrillation, familial, 10 12.5
35 atrial fibrillation, familial, 11 12.5
36 atrial fibrillation, familial, 12 12.5
37 atrial fibrillation, familial, 13 12.4
38 atrial fibrillation, familial, 14 12.4
39 atrial fibrillation and stroke 12.4
40 atrial fibrillation, familial, 18 12.4
41 atrial fibrillation, familial, 1 12.4
42 atrial fibrillation, familial, 2 12.4
43 atrial fibrillation, familial, 5 12.4
44 atrial fibrillation, familial, 8 12.4
45 long qt syndrome 10 11.9
46 brugada syndrome 7 11.8
47 pulmonary vein stenosis 11.4
48 short qt syndrome 3 11.3
49 rheumatic fever 11.3
50 pr interval, variation in 11.2

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Atrial Fibrillation:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ADRB1 GJA5 HCN4 KCNA5 KCNJ2 KCNQ1
2 homeostasis/metabolism MP:0005376 9.77 MYL4 NPPA SCN2B VKORC1 ZFHX3 ABCC9
3 muscle MP:0005369 9.28 ABCC9 ADRB1 GJA5 HCN4 KCNA5 KCNJ2

Drugs & Therapeutics for Atrial Fibrillation

PubMedHealth treatment related to Atrial Fibrillation: 59

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease. General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 504)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1951-25-3 2157
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
3
Propafenone Approved Phase 4,Phase 3,Phase 2,Phase 1 54063-53-5 4932
4
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1 959-24-0, 3930-20-9 5253
5
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
7
Clopidogrel Approved Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
8
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1 366789-02-8
9
Ticagrelor Approved Phase 4,Phase 3,Phase 1 274693-27-5 9871419
10
Warfarin Approved Phase 4,Phase 3,Phase 2 81-81-2 54678486 6691
11
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1 42399-41-7 39186
12
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
13
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
14
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Phase 2 152-72-7 54676537 9052
15
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
16
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
20
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
21
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
24
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
25
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
26
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 95635-55-5, 142387-99-3 56959
27
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
28
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206
31
Ibutilide Approved Phase 4 122647-31-8, 122647-32-9 60753
32
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51384-51-1, 37350-58-6 4171
33
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1 503612-47-3 10182969
34
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2 58-61-7 60961
35
Digoxin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-75-5 2724385 30322
36
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 46507594 772
37
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
38
Procainamide Approved Phase 4,Phase 3 51-06-9 4913
39
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1
40
Acetaminophen Approved Phase 4 103-90-2 1983
41
Nitroglycerin Approved, Investigational Phase 4,Phase 3 55-63-0 4510
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
43
Bisoprolol Approved Phase 4,Early Phase 1 66722-44-9 2405
44
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
45
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
46
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 2833 6167
47
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
48
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
49
Ephedrine Approved Phase 4 299-42-3 9294
50
Oxymetazoline Approved, Investigational Phase 4,Phase 2 1491-59-4 4636

Interventional clinical trials:

(show top 50) (show all 2116)

# Name Status NCT ID Phase Drugs
1 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
2 Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor Unknown status NCT01694394 Phase 4
3 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
4 Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
5 AF Ablation With or Without ROX Coupler Study Unknown status NCT02243891 Phase 4
6 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
7 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study Unknown status NCT01504451 Phase 4
8 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
9 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
10 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
11 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
12 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
13 Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
14 Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation Unknown status NCT01113294 Phase 4
15 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
16 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
17 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
18 Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins Unknown status NCT00605748 Phase 4
19 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
20 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
21 Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
22 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
23 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
24 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
25 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4 irbesartan;placebo
26 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
27 Corticosteroid Pulse After Ablation Unknown status NCT00807586 Phase 4 Solumedrol;Placebo
28 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
29 Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
30 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
31 Catheter Contact Force and Electrograms Unknown status NCT01587404 Phase 4
32 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
33 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
34 Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation Unknown status NCT02024230 Phase 4 Warfarin or Rivaroxaban
35 The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT Unknown status NCT00959205 Phase 4
36 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
37 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
38 The Study of Warfarin Maintenance Dose in Chinese Patients Unknown status NCT01855737 Phase 4 Warfarin
39 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4 aliskiren
40 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
41 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
42 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
43 Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Unknown status NCT01394770 Phase 4 Aliskiren
44 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
45 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
46 Anesthetic Techniques in EP Patients Unknown status NCT02664922 Phase 4 Propofol;Ketamine;Remifentanil;Sevoflurane
47 Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial Unknown status NCT02211053 Phase 4 Levothyroxine;placebo
48 Steroids In caRdiac Surgery Trial (SIRS Trial) Unknown status NCT00427388 Phase 4 Methylprednisolone
49 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
50 Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF Completed NCT01435161 Phase 4 Nifedipine,;Telmisartan

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 28

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

38
Heart, Testes, Lung, Brain, Kidney, Endothelial, Bone

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 2388)
# Title Authors Year
1
Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. ( 29340587 )
2018
2
Preventing Postoperative Atrial Fibrillation: is There One Best Option? ( 29452262 )
2018
3
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. ( 29444881 )
2018
4
Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. ( 29450893 )
2018
5
Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome in paroxysmal atrial fibrillation. ( 29446840 )
2018
6
Atrial fibrillation and stroke risk factors induce decline in creatinine clearance: Is there a specific "fibrillatory kidney disease"? ( 29306477 )
2018
7
Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis. ( 29445225 )
2018
8
The unrecognized role of tumor suppressor genes in atrial fibrillation. ( 29126922 )
2018
9
Association of lipoprotein-associated phospholipase A<sub>2</sub>and risk of incident atrial fibrillation: Findings from 3 cohorts. ( 29447785 )
2018
10
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. ( 29447773 )
2018
11
Balloon angioplasty versus stenting for pulmonary vein stenosis after pulmonary vein isolation for atrial fibrillation: A meta-analysis. ( 29273240 )
2018
12
Spontaneous massive hemothorax presenting as a late complication of stent implantation in a patient with pulmonary vein stenosis following radiofrequency ablation for atrial fibrillation. ( 29325041 )
2018
13
Ten-Year Clinical Outcome After Circumferential Pulmonary Vein Isolation Utilizing the Hamburg Approach in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation. ( 29449353 )
2018
14
Impact of the pulmonary vein orifice area assessed using intracardiac echocardiography on the outcome of radiofrequency catheter ablation for atrial fibrillation. ( 29445983 )
2018
15
New-Onset Atrial Fibrillation After PCIA orA CABGA forA Left Main Disease: The EXCEL Trial. ( 29447735 )
2018
16
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. ( 29389037 )
2018
17
Insights into atrial fibrillation newly diagnosed after stroke: Can the brain rule the heart? ( 29444967 )
2018
18
Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. ( 29444969 )
2018
19
High-Resolution Infrared Thermography of Esophageal Temperature During Radiofrequency Ablation of Atrial Fibrillation. ( 29449354 )
2018
20
Irregularity and lack of p-waves in short tachycardia episodes predict atrial fibrillation and ischemic stroke. ( 29448015 )
2018
21
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. ( 29447733 )
2018
22
Interatrial block predicts silent atrial fibrillation episodes detected by cardiac implantable electronic devices. ( 29451310 )
2018
23
Long-Term Outcomes of Post-OperativeA Atrial Fibrillation: Guilty as Charged. ( 29447736 )
2018
24
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( 29447772 )
2018
25
Role of transesophageal echocardiography during left atrial appendage occlusion device closure in a patient with non-valvular atrial fibrillation and angiodysplasia of the colon. ( 29336404 )
2018
26
Risk Factors of Recurrence of Atrial Fibrillation after AF Surgery in Patients with AF and Mitral Valve Disease. ( 29410135 )
2018
27
Hypertension, mitral valve disease, atrial fibrillation and low education level predict delirium and worst outcome after cardiac surgery in older adults. ( 29390969 )
2018
28
Safety of Direct Oral Anticoagulants versus Warfarin in Patients with Chronic Liver Disease and Atrial Fibrillation. ( 29444357 )
2018
29
Impact of antibiotic prophylaxis on catheter-associated urinary tract infections during atrial fibrillation ablation. ( 29445984 )
2018
30
Acute pericarditis following second-generation cryoballoon ablation for atrial fibrillation. ( 29445985 )
2018
31
Concealed abnormal atrial phenotype in patients with Brugada syndrome and no history of atrial fibrillation. ( 29306474 )
2018
32
Impact of Radiofrequency Ablation of Atrial Fibrillation on Pulmonary Vein Cross Sectional Area: Implications for the Diagnosis of Pulmonary Vein Stenosis. ( 29250220 )
2017
33
Alteration of Endothelin 1, MCP-1 and Chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation. ( 28886122 )
2017
34
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. ( 28087220 )
2017
35
Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study. ( 27194537 )
2017
36
Predominant obstructive or central sleep apnea in patients with atrial fibrillation: influence of characterizing apneas versus apneas and hypopneas. ( 28899542 )
2017
37
Refining Prediction of Atrial Fibrillation Risk in the General Population With Analysis of P-Wave Axis (from the Atherosclerosis Risk in Communities Study). ( 28941601 )
2017
38
Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. ( 28069838 )
2017
39
Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). ( 28950344 )
2017
40
Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation. ( 28528431 )
2017
41
Pulmonary vein stenosis or occlusion after catheter ablation of atrial fibrillation: long-term comparison of drug-eluting versus large bare metal stents. ( 29069364 )
2017
42
Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery. ( 28422282 )
2017
43
Atrial Fibrillation Screening in Nonmetropolitan Areas Using a Telehealth Surveillance System With an Embedded Cloud-Computing Algorithm: Prospective Pilot Study. ( 28951384 )
2017
44
The role of adenosine challenge in catheter ablation for atrial fibrillation: A systematic review and meta-analysis. ( 28089454 )
2017
45
Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease. ( 28942872 )
2017
46
Pulmonary Vein Isolation for Treatment of Paroxysmal Atrial Fibrillation on Patient with Situs Inversus Totalis. ( 29250224 )
2017
47
Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. ( 28951401 )
2017
48
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. ( 27748006 )
2017
49
Effect of Interleukin-27 Genetic Variants on Atrial Fibrillation Susceptibility. ( 28055231 )
2017
50
Interleukin-37 elevation in patients with atrial fibrillation. ( 28244597 )
2017

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh37 Chromosome 3, 38646328: 38646328
2 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Pathogenic/Likely pathogenic rs199473579 GRCh37 Chromosome 3, 38640469: 38640469
3 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh37 Chromosome 11, 2549192: 2549192
4 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh37 Chromosome 11, 2592575: 2592575
5 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh37 Chromosome 11, 2549189: 2549189

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

36
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 ADRB1 GJA5 SCN1B SCN2B SCN3B SCN4B
2
Show member pathways
12.61 ADRB1 KCNQ1 MYL4 SCN1B SCN4B SCN5A
3
Show member pathways
12.5 SCN1B SCN2B SCN3B SCN4B SCN5A
4
Show member pathways
12.42 ABCC9 KCNE2 KCNJ2 KCNQ1 MYL4 NPPA
5 12.39 ADRB1 SCN1B SCN2B SCN5A
6 12.19 KCNA5 KCNE2 KCNJ2 KCNQ1
7
Show member pathways